Extrait

This study is designed to demonstrate superiority of Zometa® (Zoledronic acid) 4 mg or adjusted dose based on renal function, given every 3 months over 24 months (infusion at month 0, 3, 6, 9, 12, 15, 18, and 21) in improving bone mineral density in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine or endocrine treatment compared to placebo.

Critère d'inclusion

• Hormonreceptor positive breast cancer in premenopausal women

Liens

• ictrp
• euctr